heart failure treatment Articles
-
Ancora Heart Announces Positive Safety and Efficacy Data from Study of First-of-Its-Kind Investigational Heart Failure Therapy
Interim study results from systolic heart failure patients treated with percutaneous therapy designed to improve left ventricular function presented at TCT 2019 Santa Clara, Calif.–September 25, 2019–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an interim analysis of heart failure patients treated in the CorCinch FMR ...
-
Vectorious reports positive results from VECTOR-HF I study of V-LAP system
The first clinical data of an implantable heart sensor with remote measurement capacity was presented at the prestigious ESC Heart Failure 2022 Late-Breaking Science event Israel-based Vectorious Medical Technologies announced the positive results from the VECTOR-HF I study of its V-LAP novel wireless system. The first-in-man clinical study was intended to check the safety, ease of use, and ...
By Vectorious
-
Vectorious’ in-heart microcomputer wins FDA breakthrough nod
Vectorious Medical Technologies today announced that the FDA has granted breakthrough device designation for the company’s left atrial pressure (LAP) monitoring device. The V-LAP system is the first digital, wireless, battery-free device that can communicate from deep within the body using high-resolution waveform morphology, according to the Tel Aviv-based startup. Because the pressure of ...
By Vectorious
-
Checking the outcome of different stimulation modes - Case study
This 81 year-old Lady was implanted two weeks before the measurement with a bi-ventricular pacemaker to treat her heart failure with resynchronization therapy. Different stimulation modes have been tested and their outcome in terms of stroke volume has been assessed. The stoke volume was much better in left ventricular stimulation only (LV) compared to right ventricular stimulation only (RV). ...
By PhysioFlow
-
Diagnosing heart failure with preserved ejection fraction (HFpEF)
Heart failure with preserved ejection fraction (HFpEF) has recently been recognized as the single greatest unmet need in cardiovascular medicine, overtaking heart failure with reduced ejection fraction (HFrEF) and becoming the most common form of heart failure, with a prevalence that is increasing by 1% annually.[1] Despite this, there remains no gold standard in diagnosing HFpEF. Diagnosing ...
-
What is heart failure with preserved ejection fraction (HFpEF)?
Overview What is HFpEF? Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF as the result of high left ventricular (LV) filling pressure, despite normal or near-normal LV ejection fraction (EF). Most patients with HFpEF also display normal LV volumes and an abnormal diastolic filling pattern (i.e, diastolic ...
-
What is the ICD code for HFpEF?
Heart failure with preserved ejection fraction (HFpEF) is currently affecting over half of heart failure patients. The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS), use the International Classification of Diseases (ICD) for coding ...
-
Emerging therapy for HFpEF: SGLT2 inhibitors
Recent clinical trials investigating sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions and is an increasing disease burden. [1] The prevalence of HFpEF is ...
-
Ancora Heart sees positive early results with Accucinch in systolic heart failure
Ancora Heart Inc., a Santa Clara, Calif.-based company looking to help those with heart failure, is heralding results from an interim analysis of patients treated in a U.S. early feasibility study evaluating the safety of the investigational Accucinch ventricular repair system. The multicenter, nonrandomized, prospective study is assessing the system in patients with symptomatic heart failure ...
-
Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Production
Canagliflozin is a medication used to treat type 2 diabetes. It is a third-line medication to be tried after metformin, a first-line medication for type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes. Mechanism action of Canagliflozin Canagliflozin is a sodium-glucose cotransporter (SGLT2) inhibitor. Glucose filtered in the renal tubular lumen is ...
-
Baroreflex Activation Therapy: A Novel Approach for HFrEF Patients
During the webinar, you’ll learn about: Treatment options and unmet needs of HFrEF patients The physiologic rationale of baroreflex activation Barostim therapy overview and clinical evidence overview Appropriate patient selection and real-world experience Important Safety Information CAUTION: Federal law restricts this device to sale by or on the ...
By CVRx
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you